The EP₃-agonist sulprostone, but not prosta glandin E₂ potentiates platelet aggregation in human blood

• References

• 1 Matsumoto H, Naraba H, Murakami M. et al. Concordant induction of prostaglandin E2 synthase with cyclooxygenase-2 leads to preferred production of prostaglandin E2 over thromboxane and prostaglandin D2 in lipopolysaccharide-stimulated rat peritoneal macrophages. Biochem Biophys Res Commun 1997; 230: 110-114.
• 2 Rouzer CA, Scott WA, Hamill AL. et al. Secretion of leukotriene C and other arachidonic acid meta-bolites by macrophages challenged with immunoglobulin E immune complexes. J Exp Med 1982; 156: 1077-1086.
• 3 Brock TG, McNish RW, Peters-Golden M. Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. J Biol Chem 1999; 274: 11660-11666.
• 4 Gross S, Tilly P, Hentsch D. et al. Vascular wall-produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors. J Exp Med 2007; 204: 311-320.
• 5 Paul BZ, Ashby B, Sheth SB. Distribution of pros-taglandin IP and EP receptor subtypes and isoforms in platelets and human umbilical artery smooth muscle cells. Br J Haematol 1998; 102: 1204-1211.
• 6 Fabre JE, Nguyen M, Athirakul K. et al. Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J Clin Invest 2001; 107: 603-610.
• 7 Ma H, Hara A, Xiao CY. et al. Increased bleeding tendency and decreased susceptibility to thromboembolism in mice lacking the prostaglandin E receptor subtype EP(3). Circulation 2001; 104: 1176-1180.
• 8 Matthews JS, Jones RL. Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues. Br J Pharmacol 1993; 108: 363-369.
• 9 Vezza R, Roberti R, Nenci GG. et al. Prostaglandin E2 potentiates platelet aggregation by priming protein kinase C. Blood 1993; 82: 2704-2713.
• 10 Heptinstall S, Espinosa DI, Manolopoulos P. et al. DG-041 inhibits the EP3 prostanoid receptor--a new target for inhibition of platelet function in atherothrombotic disease. Platelets 2008; 19: 605-613.
• 11 Salzman EW, Kensler PC, Levine L. Cyclic 3‘,5‘-adenosine monophosphate in human blood platelets. IV. Regulatory role of cyclic amp in platelet function. Ann NY Acad Sci 1972; 201: 61-71.
• 12 Weiss HJ, Willis AL, Kuhn D. et al. Prostaglandin E2 potentiation of platelet aggregation induced by LASS endoperoxide: absent in storage pool disease, normal after aspirin ingestion. Br J Haematol 1976; 32: 257-272.
• 13 MacIntyre DE, Gordon JL. Calcium-dependent stimulation of platelet aggregation by PGE. Nature 1975; 258: 337-339.
• 14 Gray SJ, Heptinstall S. The effects of PGE2 and CL 115,347, an antihypertensive PGE2 analogue, on human blood platelet behaviour and vascular contractility. Eur J Pharmacol 1985; 114: 129-137.
• 15 Toth O, Calatzis A, Penz S. et al. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781-788.
• 16 Awidi A, Maqablah A, Dweik M. et al. Comparison of platelet aggregation using light transmission and multiple electrode aggregometry in Glanzmann thrombasthenia. Platelets 2009; 20: 297-301.
• 17 Penz SM, Reininger AJ, Toth O. et al. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to athero-sclerotic plaques. Thromb Haemost 2007; 97: 435-443.
• 18 Breyer RM, Bagdassarian CK, Myers SA. et al. Pros-tanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001; 41: 661-690.
• 19 Israel DD, Regan JW. EP(3) prostanoid receptor iso-forms utilize distinct mechanisms to regulate ERK 1/2 activation. Biochim Biophys Acta 2009; 1791: 238-245.